Baricitinib has been the source of encouraging news for patients with Rheumatoid Arthritis this week. On June 13, 2013 both Lilly and Incyte revealed at The European League Against Rheumatism, or EULAR, that the new drug Baricitinib is an efficacious treatment option for patients with Rheumatoid Arthritis. As a Janus kinase, or JAK inhibitor, Baricitinib is effectual when used to treat various autoimmune conditions, particularly Rheumatoid Arthritis. Data from the Phase ll, 52-week study involved 201 patients who were dosed with either 4 milligrams or 8 milligrams of Baricitinib once a day. Some patients experienced a dosage increase to 8 milligrams daily at the 28 and 32 week marks, respectively, if it was determined that the increased dose was needed. Doctors in this study typically dispensed a higher dose to the aforementioned patients if they demonstrated six or more swollen and tender joints at either the 28 week or 32 week mark. This study, titled “Baricitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Study”, revealed some sizable successes early on. For example, at the end of the first 12 week period of this study the group of patients dosed with Baricitinib displayed significant progress in regard to their symptoms of Rheumatoid Arthritis, or RA. When compared to the group of patients who received a placebo for the initial 12 weeks of treatment, the participants who were administered with Baricitinib maintained a consistent improvement in their RA symptoms. In addition, this patient population showed their signs of RA to be greatly reduced, or improved even further at the end of the second 12 week period.
As an effectual JAK1 and JAK2 inhibitor, Baricitinib is currently involved in Phase lll clinical trials as a formidable treatment for RA. Baricitinib is also being explored in Phase ll studies as a potential solution for treating the signs and symptoms of both diabetic nephropathy and psoriasis. Rheumatoid Arthritis is both an inflammatory condition and an autoimmune disease, making this chronic condition challenging to treat. Patients with RA are often in excruciating, life altering pain. RA is not an uncommon condition either. This devastating disease affects 1.3 million adults in the United States. Women are three times more likely than men to be victims of RA.
LGM Pharma provides Baricitinib, CAS 1187594-09-7 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.